GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hexima Ltd (ASX:HXL) » Definitions » Intrinsic Value: Projected FCF

Hexima (ASX:HXL) Intrinsic Value: Projected FCF : A$0.00 (As of May. 23, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Hexima Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-23), Hexima's Intrinsic Value: Projected FCF is A$0.00. The stock price of Hexima is A$0.011. Therefore, Hexima's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Hexima's Intrinsic Value: Projected FCF or its related term are showing as below:

ASX:HXL's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.32
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Hexima Intrinsic Value: Projected FCF Historical Data

The historical data trend for Hexima's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hexima Intrinsic Value: Projected FCF Chart

Hexima Annual Data
Trend Jun08 Jun09 Jun10 Jun20 Jun21 Jun22 Jun23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

Hexima Semi-Annual Data
Dec06 Dec07 Jun08 Dec08 Jun09 Dec09 Jun10 Dec10 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Hexima's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Hexima's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Hexima's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Hexima's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Hexima's Price-to-Projected-FCF falls into.



Hexima Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Hexima  (ASX:HXL) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Hexima's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.011/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Hexima Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Hexima's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Hexima (ASX:HXL) Business Description

Industry
Traded in Other Exchanges
N/A
Address
84-90 Hotham Street, Corporate One, Preston, VIC, AUS, 3072
Hexima Ltd is a biotechnology company. The company is engaged in the research and development of plant-derived proteins and peptides for applications as human therapeutics.

Hexima (ASX:HXL) Headlines

From GuruFocus

Hexcel Schedules First Quarter 2022 Earnings Release and Conference Call

By Business Wire Business Wire 04-01-2022

Hexcel Declares Quarterly Dividend

By Business Wire Business Wire 07-25-2022

Hexcel Declares Quarterly Dividend

By Business Wire 10-23-2023

Hexcel Schedules Third Quarter 2020 Earnings Release and Conference Call

By Business Wire Business Wire 10-01-2020

Top 5 4th Quarter Trades of Bouvel Investment Partners, LLC

By GuruFocus Research GuruFocus Editor 01-19-2023